Current Status and Future Directions in the Development of Digital Therapeutic Interventions for Neurodevelopmental Disorders.

IF 6.3 2区医学 Q1 PHARMACOLOGY & PHARMACY

Clinical Pharmacology & Therapeutics Pub Date : 2025-03-11 DOI:10.1002/cpt.3633

Hyun-Ju Lee, Yoo Joo Jeong, Jun-Su Kim, Seung-Jae Kim, Unhui Jo, Su Jin Jun, Jongmin Lim, Jin-Yeop Park, Myungji Lee, Donggi Kim, Jeong-Heon Song, Hyang-Sook Hoe

引用次数: 0

Abstract

Innovations in digital technologies have emerged digital therapeutics (DTx) as a novel therapeutic intervention. DTx hold potential as novel theragnostics for disorders with broad diagnostic spectra, including neurodevelopmental diseases (NDDs). In this review, we highlight challenging factors in the successful development and deployment of DTx for NDDs with respect to patients, medical professionals, and manufacturers. We also discuss the implications of these factors and future directions for revitalizing DTx development for NDDs.

查看原文本刊更多论文

神经发育障碍数字化治疗干预的发展现状与未来方向。

数字技术的创新使数字疗法（DTx）成为一种新的治疗干预手段。DTx有潜力作为具有广泛诊断谱的疾病的新诊断方法，包括神经发育疾病（ndd）。在这篇综述中，我们强调了针对ndd的DTx的成功开发和部署的挑战因素，涉及患者、医疗专业人员和制造商。我们还讨论了这些因素的影响以及振兴ndd DTx发展的未来方向。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Pharmacology & Therapeutics 医学-药学

CiteScore

12.70

自引率

7.50%

发文量

290

审稿时长

2 months

期刊介绍： Clinical Pharmacology & Therapeutics (CPT) is the authoritative cross-disciplinary journal in experimental and clinical medicine devoted to publishing advances in the nature, action, efficacy, and evaluation of therapeutics. CPT welcomes original Articles in the emerging areas of translational, predictive and personalized medicine; new therapeutic modalities including gene and cell therapies; pharmacogenomics, proteomics and metabolomics; bioinformation and applied systems biology complementing areas of pharmacokinetics and pharmacodynamics, human investigation and clinical trials, pharmacovigilence, pharmacoepidemiology, pharmacometrics, and population pharmacology.